Prospective Grant of Exclusive License: Prophylactic Use of Pneumococcal Surface Adhesin A Protein, 51624-51625 [E6-14423]

Download as PDF 51624 Federal Register / Vol. 71, No. 168 / Wednesday, August 30, 2006 / Notices Atlanta, GA 30333, Telephone 404.639.2543. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: August 21, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6–14418 Filed 8–29–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Savannah River Site Dose Reconstruction Project The Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR). ACTION: CDC and ATSDR announce the following meeting. jlentini on PROD1PC65 with NOTICES AGENCY: Name: Public Meeting to Present Final Report of the Savannah River Site Dose Reconstruction Project. Time and Date: 6 p.m.–8 p.m., (Eastern Time), Tuesday, September 19, 2006. Place: University of South Carolina/ Aiken, Conference Center/Business and Education Building, Room 122, 471 University Parkway, Parking Lot ‘‘C’’, Aiken, South Carolina 29801. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people. Background: Under a Memorandum of Understanding (MOU) signed in December 1990 with DOE, and replaced by MOUs signed in 1996 and 2000, the Department of Health and Human Services (HHS) was given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production use. HHS delegated program responsibility to CDC. In addition, a memo was signed in October 1990 and renewed in November 1992, 1996, and in 2000, between VerDate Aug<31>2005 16:39 Aug 29, 2006 Jkt 208001 ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR’s public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or ‘‘Superfund’’). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other healthrelated activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles. Purpose: CDC will present the Final Report of the Savannah River Site Dose Reconstruction Project to area stakeholders and provide a forum for community interaction. This meeting will also serve as a vehicle for members of the public to express concerns to CDC. Matters To Be Discussed: The National Center for Environmental Health (NCEH) will make a presentation of the Final Report of the Savannah River Site Dose Reconstruction Project. There will be time for public questions and comments. Agenda items are subject to change as priorities dictate. Contact Person For Additional Information: Phillip R. Green, Public Health Advisor, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 1600 Clifton Road, NE., (MS–E39), Atlanta, GA 30333, telephone 404/498– 1717, fax 404/498–1811, or e-mail address: prg1@cdc.gov Dated: August 23, 2006. James D. Seligman, Chief Information Officer, Centers for Disease Control and Prevention (CDC). [FR Doc. E6–14424 Filed 8–29–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Prospective Grant of Exclusive License: Prophylactic Use of Pneumococcal Surface Adhesin A Protein as a Vaccine Office of Technology Transfer; Centers for Disease Control and Prevention (CDC); Department of Health and Human Services. AGENCY: PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 ACTION: Notice. SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Intercell, having a place of business in Vienna, Austria. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to the licensed are: U.S. Patent No. 5,422,427 entitled ‘‘Pneumococcal Fimbrial Protein A,’’ issued 06.06.95. U.S. Patent No. 6,312,944 entitled ‘‘Pneumococcal Fimbrial Protein A,’’ issued 11.06.01. U.S. Patent No. 5,854,416 entitled ‘‘Streptococcus pneumoniae 37-kDa Surface Adhesin A Protein and Nucleic Acids Coding Therefore,’’ issued 12.29.98 (CDC Ref: E–157–91/ 4). U.S. Patent No. 6,217,884 entitled ‘‘Streptococcus pneumoniae 37-kDa Surface Adhesin A Protein,’’ issued 04.17.01. U.S. Patent No. 6,773,880 entitled ‘‘Streptococcus pneumoniae 37-kDa Surface Adhesin A Protein,’’ issued 06.05.03. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. ADDRESSES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Thomas E. O’Toole, MPH, Chief Licensing Officer, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, telephone: (770) 488–8600; facsimile: (770) 488–8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within thirty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure E:\FR\FM\30AUN1.SGM 30AUN1 Federal Register / Vol. 71, No. 168 / Wednesday, August 30, 2006 / Notices Agreement will be required to receive a copy of any pending patent application. Dated: August 21, 2006. James D. Seligman, Chief Information Officer, Centers for Disease Control and Prevention. [FR Doc. E6–14423 Filed 8–29–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Advisory Committee on Special Studies Relating to the Possible LongTerm Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee); Notice of Meeting AGENCY: Food and Drug Administration, HHS. jlentini on PROD1PC65 with NOTICES ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public. Name of Committee: Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee). General Function of the Committee: To advise the Secretary and the Assistant Secretary for Health concerning its oversight of the conduct of the Ranch Hand study by the U.S. Air Force and provide scientific oversight of the Department of Veterans Affairs (VA) Army Chemical Corps Vietnam Veterans Health Study, and other studies in which the Secretary or the Assistant Secretary for Health believes involvement by the committee is desirable. Date and Time: The meeting will be held on September 7, 2006, from 8:30 a.m. to 4 p.m. Location: Food and Drug Administration, 5630 Fishers Lane, rm. 1066, Rockville, MD 20857. Contact Person: Leonard Schechtman, National Center for Toxicological Research (HFT–10), Food and Drug Administration, 5600 Fishers Lane, rm. 16–85, Rockville, MD 20857, 301–827– 6696, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512560. Please call the Information Line for up-to-date information on this meeting. Agenda: The committee will discuss the following items: (1) Summary of VerDate Aug<31>2005 16:39 Aug 29, 2006 Jkt 208001 Dioxin 2006 presentations; (2) summary of Technical Reports and manuscripts; (3) summary of transition activities. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before September 4, 2006. Oral presentations from the public will be scheduled between approximately 11:30 a.m. to 12:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 4, 2006. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Leonard Schechtman at least 7 days in advance of the meeting. FDA regrets that it was unable to publish this notice 15 days prior to the September 7, 2006, Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee) meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee) were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: August 23, 2006. Randall W. Lutter, Associate Commissioner for Policy. [FR Doc. E6–14371 Filed 8–29–06; 8:45 am] BILLING CODE 4160–01–S PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 51625 DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Proposed Collection: Comment Request In compliance with the requirement for opportunity for public comment on proposed data collection projects (section 3506(c)(2)(A) of Title 44, United States Code, as amended by the Paperwork Reduction Act of 1995, Public Law 104–13), the Health Resources and Services Administration (HRSA) publishes periodic summaries of proposed projects being developed for submission to the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, call the HRSA Reports Clearance Officer on (301) 443–1129. Comments are invited on: (a) The proposed collection of information for the proper performance of the functions of the agency; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Children’s Hospitals Graduate Medical Education Payment Program (CHGME PP) (OMB No. 0915– 0247)—Revision The CHGME PP was enacted by Public Law 106–129 to provide Federal support for graduate medical education (GME) to freestanding children’s hospitals. This legislation attempts to provide support for GME comparable to the level of Medicare GME support received by other, non-children’s hospitals. The legislation indicates that eligible children’s hospitals will receive payments for both direct and indirect medical education. Direct payments are designed to offset the expenses associated with operating approved graduate medical residency training programs and indirect payments are designed to compensate hospitals for expenses associated with the treatment of more severely ill patients and the additional costs relating to teaching residents in such programs. E:\FR\FM\30AUN1.SGM 30AUN1

Agencies

[Federal Register Volume 71, Number 168 (Wednesday, August 30, 2006)]
[Notices]
[Pages 51624-51625]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-14423]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Prophylactic Use of 
Pneumococcal Surface Adhesin A Protein as a Vaccine

AGENCY: Office of Technology Transfer; Centers for Disease Control and 
Prevention (CDC); Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide, limited 
field of use, exclusive license to practice the inventions embodied in 
the patent and patent applications referred to below to Intercell, 
having a place of business in Vienna, Austria. The patent rights in 
these inventions have been assigned to the government of the United 
States of America. The patent and patent applications to the licensed 
are: U.S. Patent No. 5,422,427 entitled ``Pneumococcal Fimbrial Protein 
A,'' issued 06.06.95.

U.S. Patent No. 6,312,944 entitled ``Pneumococcal Fimbrial Protein A,'' 
issued 11.06.01.
U.S. Patent No. 5,854,416 entitled ``Streptococcus pneumoniae 37-kDa 
Surface Adhesin A Protein and Nucleic Acids Coding Therefore,'' issued 
12.29.98 (CDC Ref: E-157-91/4).
U.S. Patent No. 6,217,884 entitled ``Streptococcus pneumoniae 37-kDa 
Surface Adhesin A Protein,'' issued 04.17.01.
U.S. Patent No. 6,773,880 entitled ``Streptococcus pneumoniae 37-kDa 
Surface Adhesin A Protein,'' issued 06.05.03.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Thomas E. O'Toole, MPH, Chief Licensing Officer, 
Technology Transfer Office, Centers for Disease Control and Prevention 
(CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, 
telephone: (770) 488-8600; facsimile: (770) 488-8615. Applications for 
a license filed in response to this notice will be treated as 
objections to the grant of the contemplated license. Only written 
comments and/or applications for a license which are received by CDC 
within thirty days of this notice will be considered. Comments and 
objections submitted in response to this notice will not be made 
available for public inspection, and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552. A signed Confidential Disclosure

[[Page 51625]]

Agreement will be required to receive a copy of any pending patent 
application.

    Dated: August 21, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
 [FR Doc. E6-14423 Filed 8-29-06; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.